论文部分内容阅读
目的:研究人体非小细胞肺癌组织中突变型p53蛋白及p53蛋白15位丝氨酸位点(p53Ser15)的磷酸化状况,p53蛋白、p53Ser15磷酸化与非小细胞肺癌临床病理特征和预后的关系。方法:分别应用酶联免疫吸附实验(ELISA)和免疫组化法检测50例非小细胞肺癌组织、相应正常肺组织及10例肺良性疾病组织中p53蛋白及p53Ser15磷酸化水平。随访观察50例非小细胞肺癌组的转移复发情况。结果:ELISA和免疫组化法均检测到p53蛋白、p53Ser15磷酸化水平在非小细胞肺癌组高于正常肺组织组和肺部良性疾病组,差异有统计学意义(P<0.001,P<0.05)。免疫组化方法检测p53蛋白、p53[pS15]阳性率在淋巴结转移组显著高于无转移组(P<0.05)。随访期内5例出现复发或远处转移的病例p53蛋白、p53[pS15]表达水平高于本组未复发转移病例(P<0.05)。结论:ELISA方法做p53[pS15]、p53蛋白的定量分析是可行的。p53蛋白、p53[pS15]高水平表达可能会有助于肿瘤进展更快。
Objective: To investigate the relationship between the phosphorylation of mutant p53 protein and the p53 ser15 site (p53Ser15), p53 protein, p53Ser15 phosphorylation and the clinicopathological features and prognosis of non-small cell lung cancer (NSCLC). Methods: The phosphorylation levels of p53 protein and p53Ser15 in 50 non-small cell lung cancer tissues, corresponding normal lung tissues and 10 benign lung tissues were detected by enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry respectively. Follow-up observation of 50 cases of non-small cell lung cancer metastasis recurrence. Results: The p53 protein was detected by ELISA and immunohistochemistry. The phosphorylation level of p53Ser15 in non-small cell lung cancer group was higher than that in normal lung group and benign lung disease group, the difference was statistically significant (P <0.001, P <0.05 ). The positive rate of p53 [pS15] in the lymph node metastasis group was significantly higher than that in the non-metastasis group (P <0.05) by immunohistochemistry. In the follow-up period, the expression of p53 protein and p53 [pS15] in 5 cases with recurrent or distant metastasis were higher than those without recurrence (P <0.05). Conclusion: Quantitative analysis of p53 [pS15] and p53 protein by ELISA is feasible. High levels of p53 protein, p53 [pS15], may contribute to tumor progression faster.